János Almássy

Dr. János Almássy


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CDCsaba Bálint Dienes
Csaba Bálint Dienes
ZKZsigmond Kovács
Zsigmond Kovács
THTamás Hézső
Tamás Hézső
JAJános Almássy
János Almássy
JMJanos Magyar
Janos Magyar
NSNorbert Szentandrássy
Norbert Szentandrássy
Transient receptor potential melastatin 4 (TRPM4) is a unique member of the TRPM protein family and, similarly to TRPM5, is Ca2+ sensitive and permeable for monovalent but not divalent cations. It is widely expressed in many organs and is involved in several functions; it regulates membrane potential and Ca2+ homeostasis in both excitable and non-excitable cells. This part of the review discusses the currently available knowledge about the physiological and pathophysiological roles of TRPM4 in various tissues. These include the physiological functions of TRPM4 in the cells of the Langerhans islets of the pancreas, in various immune functions, in the regulation of vascular tone, in respiratory and other neuronal activities, in chemosensation, and in renal and cardiac physiology. TRPM4 contributes to pathological conditions such as overactive bladder, endothelial dysfunction, various types of malignant diseases and central nervous system conditions including stroke and injuries as well as in cardiac conditions such as arrhythmias, hypertrophy, and ischemia-reperfusion injuries. TRPM4 claims more and more attention and is likely to be the topic of research in the future.

Verified
Journal Article
Open access
PDF file
Mónika SztretyeMónika Sztretye
Mónika Sztretye
LSLászló Szabó
László Szabó
NDNóra Dobrosi
Nóra Dobrosi
JFJános Fodor
János Fodor
PSPéter Szentesi
Péter Szentesi
LCLászló Csernoch
László Csernoch
Muscular dystrophies are a group of more than 160 different human neuromuscular disorders characterized by a progressive deterioration of muscle mass and strength. The causes, symptoms, age of onset, severity, and progression vary depending on the exact time point of diagnosis and the entity. Congenital myopathies are rare muscle diseases mostly present at birth that result from genetic defects. There are no known cures for congenital myopathies; however, recent advances in gene therapy are promising tools in providing treatment. This review gives an overview of the mouse models used to investigate the most common muscular dystrophies and congenital myopathies with emphasis on their potentials and limitations in respect to human applications.

29 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PNPeter Nanasi
Peter Nanasi
BHBalazs Horvath
Balazs Horvath
FTFábián Tar
Fábián Tar
JAJános Almássy
János Almássy
NSNorbert Szentandrássy
Norbert Szentandrássy
AVAndras Varro
Andras Varro
Due to the limited availability of healthy human ventricular tissues, the most suitable animal model has to be applied for electrophysiological and pharmacological studies. This can be best identified by studying the properties of ion currents shaping the action potential in the frequently used laboratory animals, such as dogs, rabbits, guinea pigs, or rats, and comparing them to those of human cardiomyocytes. The authors of this article with the experience of three decades of electrophysiological studies, performed in mammalian and human ventricular tissues and isolated cardiomyocytes, summarize their results obtained regarding the major canine and human cardiac ion currents. Accordingly, L-type Ca2+ current (ICa), late Na+ current (INa-late), rapid and slow components of the delayed rectifier K+ current (IKr and IKs, respectively), inward rectifier K+ current (IK1), transient outward K+ current (Ito1), and Na+/Ca2+ exchange current (INCX) were characterized and compared. Importantly, many of these measurements were performed using the action potential voltage clamp technique allowing for visualization of the actual current profiles flowing during the ventricular action potential. Densities and shapes of these ion currents, as well as the action potential configuration, were similar in human and canine ventricular cells, except for the density of IK1 and the recovery kinetics of Ito. IK1 displayed a largely four-fold larger density in canine than human myocytes, and Ito recovery from inactivation displayed a somewhat different time course in the two species. On the basis of these results, it is concluded that canine ventricular cells represent a reasonably good model for human myocytes for electrophysiological studies, however, it must be borne in mind that due to their stronger IK1, the repolarization reserve is more pronounced in canine cells, and moderate differences in the frequency-dependent repolarization patterns can also be anticipated.

27 July 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
GDGyula Diszházi
Gyula Diszházi
ZMZsuzsanna É. Magyar
Zsuzsanna É. Magyar
ELErika Lisztes
Erika Lisztes
Edit Tóth-MolnárEdit Tóth-Molnár
Edit Tóth-Molnár
PNPéter P. Nánási
Péter P. Nánási
JAJános Almássy
János Almássy
Transient receptor potential cation channel subfamily M member 4 (TRPM4) is a Ca2+-activated nonselective cation channel that mediates membrane depolarization. Although, a current with the hallmarks of a TRPM4-mediated current has been previously reported in pancreatic acinar cells (PACs), the role of TRPM4 in the regulation of acinar cell function has not yet been explored. In the present study, we identify this TRPM4 current and describe its role in context of Ca2+ signaling of PACs using pharmacological tools and TRPM4-deficient mice. We found a significant Ca2+-activated cation current in PACs that was sensitive to the TRPM4 inhibitors 9-phenanthrol and 4-chloro-2-[[2-(2-chlorophenoxy)acetyl]amino]benzoic acid (CBA). We demonstrated that the CBA-sensitive current was responsible for a Ca2+-dependent depolarization of PACs from a resting membrane potential of -44.4 ± 2.9 to -27.7 ± 3 mV. Furthermore, we showed that Ca2+ influx was higher in the TRPM4 KO- and CBA-treated PACs than in control cells. As hormone-induced repetitive Ca2+ transients partially rely on Ca2+ influx in PACs, the role of TRPM4 was also assessed on Ca2+ oscillations elicited by physiologically relevant concentrations of the cholecystokinin analog cerulein. These data show that the amplitude of Ca2+ signals was significantly higher in TRPM4 KO than in control PACs. Our results suggest that PACs are depolarized by TRPM4 currents to an extent that results in a significant reduction of the inward driving force for Ca2+. In conclusion, TRPM4 links intracellular Ca2+ signaling to membrane potential as a negative feedback regulator of Ca2+ entry in PACs.

10 January 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ZKZsigmond Kovács
Zsigmond Kovács
CDCsaba Bálint Dienes
Csaba Bálint Dienes
THTamás Hézső
Tamás Hézső
JAJános Almássy
János Almássy
JMJanos Magyar
Janos Magyar
NSNorbert Szentandrássy
Norbert Szentandrássy
Transient receptor potential melastatin 4 is a unique member of the TRPM protein family and, similarly to TRPM5, is Ca2+-sensitive and permeable to monovalent but not divalent cations. It is widely expressed in many organs and is involved in several functions by regulating the membrane potential and Ca2+ homeostasis in both excitable and non-excitable cells. This part of the review discusses the pharmacological modulation of TRPM4 by listing, comparing, and describing both endogenous and exogenous activators and inhibitors of the ion channel. Moreover, other strategies used to study TRPM4 functions are listed and described. These strategies include siRNA-mediated silencing of TRPM4, dominant-negative TRPM4 variants, and anti-TRPM4 antibodies. TRPM4 is receiving more and more attention and is likely to be the topic of research in the future.

1 September 2019 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
GDGyula Diszházi
Gyula Diszházi
ZMZsuzsanna Édua Magyar
Zsuzsanna Édua Magyar
JMJános András Mótyán
János András Mótyán
LCLászló Csernoch
László Csernoch
IJIstván Jóna
István Jóna
JAJános Almássy
János Almássy
Dantrolene is a ryanodine receptor (RyR) inhibitor, which is used to relax muscles in malignant hyperthermia syndrome. Although dantrolene binds to the RyR protein, its mechanism of action is unknown, mainly because of the controversial data showing that dantrolene inhibited Ca2+-release from intact fibers and sarcoplasmic reticulum (SR) vesicles, but failed to inhibit single ryanodine receptor (RyR) channel currents in bilayers. Accordingly, it was concluded that an important factor for dantrolene`s action was lost during the purification procedure of RyR. Recently, Mg2+ was demonstrated to be the essential factor for dantrolene to inhibit Ca2+- release in skinned muscle fibers. The aim of the present study was to confirm these results in Ca2+ release- and bilayer experiments, using SR vesicles and solubilized channels, respectively. Our Ca2+-release experiments demonstrated that the effect of dantrolene and Mg2+ was cooperative; and that ATP enhanced the inhibiting effect of dantrolene. Namely, 10 µM dantrolene reduced RyR channel open probability by ~50% in the presence of 3 mM free Mg2+ and 1 mM ATP, while channel activity further decreased to ~20% of control when [ATP] was increased to 2 mM. Our data provide important complementary information that support the direct, Mg2+-dependent mechanism of dantrolene9s action and suggest that dantrolene also requires ATP to inhibit RyR. SIGNIFICANCE STATEMENT The muscle relaxant dantrolene acts on ryanodine receptor in the presence of magnesium and ATP, which should be considered in therapy.